3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Lung Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Neoplasm Metastasis
2
Endometrial Neoplasms
2
Breast Neoplasms
2
Triple Negative Breast Neoplasms
1
Thoracic Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Salivary Gland Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Myelodysplastic Syndromes
1
Lung Diseases
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia
1
High Grade Serous Carcinoma
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Cholangiocarcinoma
1
Carcinosarcoma
1
Carcinoma, Transitional Cell
1
Carcinoma, Squamous Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Bronchogenic
1
Bronchial Neoplasms
1
Interventions
Carboplatin
3
pembrolizumab
2
durvalumab
2
Pemetrexed
2
Cisplatin
2
selpercatinib
1
repotrectinib
1
pralsetinib
1
ceralasertib
1
Paclitaxel
1
Gemcitabine
1
Bevacizumab
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Respiratory Tract Diseases
×
ceralasertib
×
90 days
×
Clear all
NCT05941897
2026-03-05
LOTOS
AstraZeneca
Phase 2
Active not recruiting
39 enrolled